March 2010. Volume 6. Number 1

Economic Assessment in Medicine (III): Review of guidelines for conducting economic evaluations. Instruments for assessing the methodological quality

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

MBE | Bases of evidence based medicine

Authors: Costi M1, González de Dios J2, Sacristán JA3.
1Departamento Médico Lilly. Madrid. España.
2Departamento de Pediatría. Hospital General Universitario de Alicante. España.
3Departamento Médico Lilly. Alcobendas. Madrid. España.
Correspondence: María Costi. Email: costiruiz@yahoo.es
Reception date: 24/02/2010
Acceptance date: 01/03/2010
Publication date: 25/03/2010

How to cite this article

Costi M, González de Dios J, Sacristán JA. Evaluación Económica en Medicina (III): Revisión de las directrices para la realización de evaluaciones económicas. Instrumentos de valoración de la calidad metodológica. Evid Pediatr. 2010;6:20.

MBE | Bases of evidence based medicine

Authors: Costi M1, González de Dios J2, Sacristán JA3.
1Departamento Médico Lilly. Madrid. España.
2Departamento de Pediatría. Hospital General Universitario de Alicante. España.
3Departamento Médico Lilly. Alcobendas. Madrid. España.
Correspondence: María Costi. Email: costiruiz@yahoo.es
Reception date: 24/02/2010
Acceptance date: 01/03/2010
Publication date: 25/03/2010

How to cite this article

Costi M, González de Dios J, Sacristán JA. Evaluación Económica en Medicina (III): Revisión de las directrices para la realización de evaluaciones económicas. Instrumentos de valoración de la calidad metodológica. Evid Pediatr. 2010;6:20.

References

  1. Dilla T, González de Dios J, Sacristán JA. Evaluación Económica en Medicina (I): Fundamentos y Metodología. Evid Pediatr. 2009;5:71.
  2. Valladares A, González de Dios J, Sacristán JA. Evaluación Económica en Medicina (II): Métodos de evaluación económica y manejo de la incertidumbre asociada. Evid Pediatr. 2009;5:88.
  3. Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 2009;302):1437-43.
  4. López Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J et al. Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias. Gac Sanit 2009 doi:10.1016/j.gaceta 2009.07.011.
  5. Drummond M, Sculpher M. Better analysis for better decisions: has pharmacoeconomics come of age? Pharmacoeconomics. 2006;24:107-8.
  6. Jönsson B , Staginnus U. Nuevas reformas sanitarias y el rol de la evaluación económica en España: ¿hay perspectivas de un NICE español? Rev Esp Econ Salud. 2006;5:80-84.
  7. Morgan SG, McMahon M, Mitton C, Roughead E, Kirk R, Kanavos P et al.Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom. Health Aff (Millwood). 2006;25:337-47.
  8. Steinbrook R. Saying no isn?t NICE: the travails of Britain`s National Institute for Health and Clinical Excellence. N Engl J Med. 2008;359:1977-81.
  9. Harris AH, Hill SR, Chin G, Li JJ, Walkom E. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis1994-2004. Med Decis Making. 2008;28:713-22.
  10. Henry DA, Hill SR, Harris A. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme. JAMA. 2005;294:2630-2.
  11. Tierney M, Manns B; Members of the Canadian Expert Drug Advisory Committee. Optimizing the use of prescription drugs in Canada through the Common Drug Review. CMAJ. 2008;178:432-5.
  12. McMahon M, Morgan S, Mitton C. The CommonDrug Review: a NICE start for Canada? Health Policy. 2006;77:339-51.
  13. Rovira J, Antoñanzas F. Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation. Pharmacoeconomics. 1995;8:245-52.
  14. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. Londres, NICE, 2008.
  15. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) (versión 4.3). PBS PublicationsDepartment of Health and Ageing, Australian Government, 2008.
  16. Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006.
  17. National Institute for Health and Clinical Excellence. Scientific advice consultancy service. [Fecha de consulta: 4 de febrero de 2010]. Disponible en: http://www.nice.org.uk/aboutnice/scientificadvice/AboutScientificAdvice.jsp.
  18. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines-similarities, differences and some implications. Value Health. 2001;4:225-50.
  19. Sacristán JA, Dilla T, Luis Pinto J, Antoñanzas F. Evaluación económica de medicamentos: experiencias y vías de avance. Gac Sanit. 2008;22:354-7.
  20. Pinto JL, Sacristán JA, Antoñanzas F. Reflexiones sobre reglas de decisión, coste-efectividad e impacto presupuestario. Gac Sanit. 2008;22:585-9.
  21. Ungar WJ, Santos MT. The Pediatric Economic Database Evaluation (PEDE) project. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2002.
  22. García-Altés A. La introducción de tecnologías en los sistemas sanitarios: del dicho al hecho. Gac Sanit. 2004;18:398-405.
  23. Neumann PJ, Fang CH, Cohen JT. 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement. Pharmacoeconomics.2009;27:861-72.
  24. Oliva J, Del Llano J, Sacristán JA. Análisis de las evaluaciones económicas de tecnologías sanitarias realizadas en España en la década 1990-2000. Gac Sanit. 2002; Suppl 2:2-11.
  25. Drummond MF, Sculpher MJ, Torrance GW,O? Brien BJ y Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd Edition. Oxford: Oxford University Press; 2005.
  26. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83.
  27. Instructions for Authors for Preparation of Manuscripts for PharmacoEconomics. [Fecha de consulta: 4 de febrero de 2010]. Disponible en : http://pt.wkhealth.com/pt/pt-core/template-adis/phe/media/IFA.pdf
  28. Checklist for authors. Journal of Medical Economics Authors Guidelines. [Fecha de consulta: 4 de febrero de 2010]. Disponible en: www.pjbpubs.com/uploads/downloads/JME_guidelines.pdf.
  29. Antoñanzas F. Artículos de evaluación económica en Gaceta Sanitaria algunas reflexiones. Gac Sanit. 2003;17:351-2.
  30. Sacristán JA, Soto J y Galende l. Evaluation ofpharmacoeconomic studies: utilization of a checklist. Ann Pharmacother 1993;27:1126-33.
  31. Bradley CA, Iskedjian M, Lanctot KL, Mittmann N, Simone C, St Pierre E et al. Quality assessment of economic evaluations in selected pharmacy,medical, and health economics journals. Ann Pharmacother 1995;29(Pt 7):681-9.
  32. Iskedjian M, Trakas K, Bradley CA, Addis A, Lanctôt K, Kruk D et al. Quality assessment of economic evaluations published in PharmacoEconomics. The first four years (1992 to 1995). Pharmacoeconomics. 1997;12:685-94.
  33. Ungar WJ, Santos MT. The Pediatric Quality Appraisal Questionnaire: an instrument for evaluation of the pediatric health economics literature. Value Health. 2003;6:584-94.
  34. Ungar WJ, Santos MT. Quality appraisal of pediatric health economic evaluations. Int J Technol Assess Health Care. 2005;21:203-10.
  35. National Institute for Health and Clinical Excellence. The guidelines manual(appendices). Appendix H. Methodology checklist:economic evaluations. Londres, NICE,2009.
  36. Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006. Appendix 3.
  37. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253-8.
  38. Ofman JJ, Sullivan SD, Neumann PJ, Chiou CF, Henning JM, Wade SW et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003;9:53-61.
  39. Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int J Technol Assess Health Care. 2005;21:240-5.
  40. Abellán Perpiñán JM, Sánchez Martínez FI, Martínez Pérez JE. La medición de la calidad de los estudios de evaluación económica. Una propuesta de “checklist” para la toma de decisiones. Rev Esp Salud Publica. 2009;83:71-84.
25/03/2010

Linked Comment